相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Letter
Immunology
Pragya D. Yadav et al.
CLINICAL INFECTIOUS DISEASES
(2022)
Letter
Immunology
Pragya D. Yadav et al.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Biochemistry & Molecular Biology
Emma C. Thomson et al.
Summary: SARS-CoV-2 virus can mutate and evade immunity, with mutations like N439K conferring resistance against neutralizing monoclonal antibodies and enhancing binding affinity to hACE2 receptor. Despite similar in vitro replication fitness and clinical outcomes compared to wild type, N439K mutation highlights the importance of ongoing molecular surveillance for guiding vaccine and therapeutic development and usage.
Article
Biochemistry & Molecular Biology
Wilfredo F. Garcia-Beltran et al.
Summary: New variants of SARS-CoV-2 show high resistance to vaccine neutralization, with some able to escape vaccine responses with just a few mutations, highlighting the importance of developing broadly protective measures against variants.
Article
Microbiology
Xiaoying Shen et al.
Summary: Current COVID-19 vaccines target the ancestral SARS-CoV-2 spike, but the emerging B.1.1.7 variant with multiple spike mutations may impact some antibody therapies while posing no major concerns for vaccine efficacy or increased risk of reinfection.
CELL HOST & MICROBE
(2021)
Letter
Immunology
Noemie Zucman et al.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Multidisciplinary Sciences
Pengfei Wang et al.
Summary: The COVID-19 pandemic has had global repercussions, with promising vaccines and monoclonal antibody therapies. However, newly detected variants of SARS-CoV-2 present challenges to these treatment options.
Article
Biochemistry & Molecular Biology
Constantinos Kurt Wibmer et al.
Summary: The SARS-CoV-2 virus in the B.1.351 variant discovered in South Africa can evade neutralization by most antibodies when expressed, but does not affect binding by convalescent plasma. This suggests the potential for reinfection with antigenically distinct variants and predicts reduced efficacy of spike-based vaccines.
Article
Biochemistry & Molecular Biology
Xuping Xie et al.
Summary: The study found that human sera from recipients of the BNT162b2 vaccine can neutralize SARS-CoV-2 viruses containing key spike mutations from the newly emerged UK and SA variants.
Letter
Medicine, General & Internal
Kai Wu et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Alexander Muik et al.
Summary: A new SARS-CoV-2 lineage B.1.1.7 has emerged in the UK, which is more transmissible and faster spreading than other strains. However, a study found that the BNT162b2 vaccine offers largely preserved protection against the B.1.1.7 lineage, despite some reduced neutralizing titers.
Article
Cell Biology
Chloe Rees-Spear et al.
Summary: The study found that emerging variants of the coronavirus may lead to reduced neutralization by antibodies induced by vaccines or previous infection, but some samples still retain effectiveness. This highlights the importance of real-time monitoring of emerging mutations and their impact on vaccine efficacy.
Letter
Allergy
Xinyue Chang et al.
Article
Microbiology
Alona Kuzmina et al.
Summary: Vaccines that induce high levels of neutralizing antibodies are crucial in combating COVID-19, but some variants of SARS-CoV-2 show resistance to neutralization, raising concerns about vaccine efficacy.
CELL HOST & MICROBE
(2021)
Article
Microbiology
Pengfei Wang et al.
Summary: The emerging Brazilian variant P.1 shows increased resistance to antibody neutralization, posing a threat to current antibody therapies, but has less impact on the effectiveness of protective vaccines.
CELL HOST & MICROBE
(2021)
Letter
Medicine, General & Internal
Venkata Viswanadh Edara et al.
Summary: This study investigates the neutralizing antibody response to 4 SARS-CoV-2 variants in individuals who have been infected or vaccinated.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Editorial Material
Public, Environmental & Occupational Health
Gajanan Sapkal et al.
JOURNAL OF TRAVEL MEDICINE
(2021)
Article
Multidisciplinary Sciences
Sandile Cele et al.
Summary: The study compared the neutralization of non-VOC and 501Y.V2 VOC variants using plasma from COVID-19 patients in South Africa. It found that plasma from individuals infected during the first wave effectively neutralized the first-wave virus variant, while plasma from those infected in the second wave effectively neutralized the 501Y.V2 variant.
Article
Biochemistry & Molecular Biology
Delphine Planas et al.
Summary: The ability of convalescent sera from individuals with coronavirus disease 2019 and those vaccinated with BNT162b2 to neutralize SARS-CoV-2 variants B1.1.7 and B.1.351 decreases, but increases after two vaccine doses. The study found that the B.1.1.7 and B.1.351 variants may have acquired partial resistance to neutralizing antibodies generated by natural infection or vaccination, particularly in individuals with low antibody levels. This suggests that the B.1.351 variant may pose a greater risk of infection in immunized individuals.
Article
Biochemistry & Molecular Biology
David S. Khoury et al.
Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.
Letter
Medicine, General & Internal
Laith J. Abu-Raddad et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
S. A. Madhi et al.
Summary: The ChAdOx1 nCoV-19 vaccine did not provide significant protection against mild-to-moderate Covid-19 caused by the B.1.351 variant, with an efficacy of 10.4%. The incidence of serious adverse events was balanced between the vaccine and placebo groups.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
V. Shinde et al.
Summary: The NVX-CoV2373 vaccine showed efficacy in preventing Covid-19, with higher vaccine efficacy observed among HIV-negative participants. Most infections were caused by the B.1.351 variant.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Leonidas Stamatatos et al.
Summary: The study found that vaccination of both previously infected individuals and those who were not infected resulted in increased neutralizing antibody titers, with previously infected individuals showing a greater boost in neutralizing titers. Vaccination of naive individuals also elicited cross-neutralizing responses, but at lower titers.
Editorial Material
Biotechnology & Applied Microbiology
Daniele Focosi et al.
Summary: SARS-CoV-2 has infected over 122 million people worldwide, with COVID-19 vaccines in short supply. The need for boosting vaccine response in convalescents after the first dose remains uncertain, but mounting evidence suggests convalescents develop antibody levels similar to naive vaccinees after a single dose. Optimizing vaccine delivery to convalescents may be effective in accelerating the achievement of herd immunity.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2021)
Article
Public, Environmental & Occupational Health
Mark S. Graham et al.
Summary: The study showed that the B.1.1.7 variant did not result in changes in COVID-19 symptoms or duration of illness, and there was no significant increase in reinfection rate compared to previous variants.
LANCET PUBLIC HEALTH
(2021)
Letter
Infectious Diseases
Yuxin Chen et al.
LANCET INFECTIOUS DISEASES
(2021)
Article
Biochemistry & Molecular Biology
Talia Kustin et al.
Summary: Breakthrough SARS-CoV-2 infections post-vaccination may be caused by B.1.1.7 or B.1.351 variants, indicating the importance of robust vaccination. Reduced vaccine effectiveness against these variants was observed in the study, highlighting the need for continued surveillance and enhanced vaccination efforts.
Article
Virology
Benjamin Trinite et al.
Summary: The study found that the time from natural infection and the nature of the infecting variant determined cross-neutralization; Uninfected vaccinees showed a small reduction in neutralization against the B.1.1.7 variant; Previously infected individuals developed more robust neutralizing responses against B.1.1.7 after vaccination, indicating that vaccines can enhance the neutralization breadth conferred by natural infection.
Article
Multidisciplinary Sciences
Matthias Becker et al.
Summary: This study characterizes the antibody response from vaccinated, infected, and uninfected individuals against emerging variants of concern of SARS-CoV-2, indicating reduced neutralization of a South African isolate. High IgG titers in the saliva of vaccinees suggest reduced transmission potential.
NATURE COMMUNICATIONS
(2021)
Letter
Immunology
David Harrington et al.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Medicine, Research & Experimental
Haolin Liu et al.
Summary: The newly emerging variants of SARS-CoV-2 from South Africa and Brazil have led to a higher infection rate and reinfection of COVID-19 patients. Mutations within the receptor-binding domains of the virus increase binding affinity to the human receptor ACE2 and affect the binding of therapeutic antibodies.
Letter
Immunology
Carolina Kymie Vasques Nonaka et al.
Summary: The case of reinfection from distinct virus lineages in Brazil with the E484K mutation raises concerns about the duration of protective immune responses against SARS-CoV-2, especially with the variant associated with escape from neutralizing antibodies. This highlights potential challenges for virus control measures.
EMERGING INFECTIOUS DISEASES
(2021)
Article
Cell Biology
Tyler N. Starr et al.
Summary: The study mapped mutations to the SARS-CoV-2 spike receptor-binding domain that escape binding by certain monoclonal antibodies. These mutations are concentrated in specific lineages of SARS-CoV-2. The authors suggest diversifying the epitopes targeted by antibodies and antibody cocktails to make them more resilient to SARS-CoV-2 antigenic evolution.
CELL REPORTS MEDICINE
(2021)
